Details coming soon! Subscribe to our daily email report to find out more.

BIO 2018: The ROI in R&D

Endpoints News editor John Carroll is bringing together some of the world’s top authorities on designing and executing an R&D strategy that will deliver the maximum return on investment. After falling steadily over the past decade, there’s an unprecedented push to create a profitable and sustainable strategy for developing new drugs and finally delivering a boost on ROI. What have the top players done right, and where have they gone wrong? What role will AI and other new technologies play in improving R&D efficiency? And how will these ideas influence the work now underway at your biotech company? This is a discussion that centers on the biggest issues now confronting the $160 billion drug R&D industry. And you won’t want to miss out.

Event Details

  • When: Tuesday, 5 June 2018 7:00—8:30am ET
  • Where: Westin Boston Waterfront
  • Format: Seated Breakfast and Panel Discussion

Need help? Get help or email:


Thomas Lynch
CSO, Bristol-Myers Squibb

Karen Young
US Pharma Leader, PwC

Gary Nabel
CSO, Sanofi

David Altshuler
CSO, Vertex

Mathai Mammen
Global R&D Head, J&J